

USSN 10/820,582

LPT-3001-DV

AMENDMENT

Please amend the claims as follows:

1. (currently amended) A method for treating cancer ~~a disease or disorder~~ in a patient, comprising administering to a patient an effective amount of an agent that binds a sphingolipid or a sphingolipid metabolite to reduce the effective concentration thereof, wherein the agent treats ~~a disease or disorder~~ is selected from the group consisting of cancer, angiogenesis, and inflammation.
2. (currently amended) ~~The~~ A method according to ~~of~~ claim 1, wherein said agent is an antibody or antibody derivative.
3. (cancelled)
4. (cancelled)
5. (currently amended) ~~The~~ A method according to ~~of~~ claim 1, wherein said sphingolipid or sphingolipid metabolite is selected from the group consisting of sphingomyelin, sphingosine, ~~sphingolipid 1-phosphate~~ sphingosine-1-phosphate (S-1-P), ceramide, sphingolipophorylcholine (SPC), 3-ketosphinganine, galactosylceramide, and dihydroceramide.
6. (currently amended) ~~The~~ A method according to ~~of~~ claim 1, wherein said sphingolipid is selected from the group consisting of ceramide, sphingosine, and sphingolipid 1-phosphate sphingosine-1-phosphate (S-1-P).
7. (currently amended) ~~The~~ A method according to ~~of claim 1~~ claim 4, wherein said sphingolipid is ~~sphingolipid 1-phosphate~~ sphingosine-1-phosphate (S-1-P).
- 8-15. (canceled)